Prime Highlights
- Dr. Reddy’s Laboratories has launched Bosutinib Tablets 400 mg in the US, becoming the first company to introduce a generic version of Bosulif at this dosage strength.
- The product qualifies for 180 days of generic exclusivity, giving the company a temporary period of limited competition in the US market.
Key Facts
- Dr. Reddy’s Laboratories is a leading Indian pharmaceutical company with a strong presence in oncology, generics, and specialty medicines across global markets.
- The reference drug Bosulif 400 mg recorded US sales of about $253.8 million during the 12 months ended April 2026, according to IQVIA data.
Background
Shares of Dr Reddy’s Laboratories are expected to remain in focus after the company announced the launch of Bosutinib Tablets 400 mg in the United States, marking the first generic version of Bosulif available in the market.
The launch expands the company’s oncology portfolio and supports its strategy of improving access to affordable treatment options for patients. Dr Reddy’s introduced the product through a partnership with MSN Laboratories, under which MSN managed the development and manufacturing of the medicine, while Dr Reddy’s received exclusive rights to market it in the US.
The company said Bosutinib Tablets 400 mg was filed under the first-to-file category, making it eligible for 180 days of generic drug exclusivity in the US for this dosage strength. The exclusivity period provides the first generic entrant with a temporary advantage by limiting direct competition, which could help the company strengthen its market position.
According to industry data from IQVIA, the reference drug Bosulif 400 mg generated approximately $253.8 million in US sales during the 12 months ended April 2026, highlighting the market opportunity for the generic version.
Milan Kalawadia, Chief Executive Officer of North America at Dr Reddy’s Laboratories, said the launch demonstrates the company’s commitment to bringing important therapies to market quickly while improving affordability and access for patients and healthcare providers. He added that the company remains focused on expanding its oncology portfolio and strengthening industry partnerships.
Bharat Reddy, Executive Director at MSN Laboratories, said the launch reflects the company’s expertise in developing and manufacturing complex oncology medicines while supporting wider access to affordable healthcare worldwide.
Dr Reddy’s shares closed the previous trading session marginally lower at ₹1,272.90. The stock has gained about 2% so far in 2026.
